Niagen Bioscience Partners with OneSpaWorld to Bring NAD-Boosting Benefits of Niagen IV to High Seas.
ByAinvest
Tuesday, Mar 31, 2026 8:37 am ET1min read
NAGE--
OSW--
Niagen Bioscience has partnered with OneSpaWorld to offer Niagen IV, a pharmaceutical-grade NAD+ booster, at over 80 Medi-Spa clinics on high-end cruise ships. This marks Niagen Bioscience's first cruise ship clinic partnership, expanding its Niagen Plus clinic footprint and reaching a new premium channel. Niagen Bioscience's Niagen IV formulation offers a better patient experience and higher NAD+ blood levels without severe side effects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet